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Abstract
Purpose The rationale for the present study was to evaluate
the predictive role of 99mTc-infliximab scintigraphy in therapy
decision-making in patients with refractory monoarthritis and
also candidates for intraarticular (IA) infliximab treatment.
Methods We studied 12 patients (5 with rheumatoid arthritis
and 7 with spondyloarthropathy) with active monoarthritis
(11 knees and 1 ankle) that had lasted for at least 3 months.
Patients were evaluated clinically and ultrasonographically
at baseline and 12 weeks after IA administration of inflix-
imab. At the same time-points, 99mTc-infliximab scintigra-
phy was performed: planar anterior and posterior images of
arthritic joints were acquired at 6 and 20 h after injection
and target-to-background (T/B) ratios were calculated.
Results After treatment, a significant improvement in
clinical and ultrasonographic parameters was recorded in
six patients. Three patients had a partial response and
three did not respond. Regarding scintigraphic evaluation,
the T/B ratio analysis showed a significantly higher up-
take in affected than in nonaffected joints before therapy
(1.78±0.46 vs. 1.29±0.27, p00.006 at 6 h; 2.05±0.50 vs.
1.41±0.36 at 20 h, p00.002), and mean uptake at 20 h was
also significantly higher than at 6 h (p00.0004). Scintigraphy
showed a significant decrease in posttherapy T/B ratios of the
affected joints (p00.0001 at 6 h and p00.0001 at 20 h),
indicating a reduction in TNF into the affected joints. Most
importantly, responders showed a significantly higher percent-
age increase in pretherapy uptake from 6 h to 20 h in the
affected joints than nonresponders (p00.00001).
Conclusion The results of the present investigation suggest
that 99mTc-infliximab scintigraphy could be a useful tool to
predict the clinical response to IA infliximab treatment in
patients with refractory monoarthritis.
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making
Introduction
TNFα has been identified as a key cytokine in inflammatory
arthropathies with a pathophysiological role, promoting sy-
novial inflammation and erosion of bone and cartilage [1,
2]. TNF antagonists have demonstrated good efficacy in the
treatment of patients with rheumatoid arthritis (RA) and a
spondyloarthropathy (SpA), such as psoriatic arthritis (PsA),
leading to a significant clinical improvement in many
patients resistant to conventional therapies [3]. In the last
few years, some experience with intraarticular (IA) treat-
ment with TNF antagonists in patients with refractory
monoarthritis has been reported. The majority of these
patients have been treated with infliximab, and only a few
studies have evaluated the efficacy of etanercept and adali-
mumab IA treatment [4–15].
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Observational studies investigating the clinical efficacy
of IA treatment with a TNF antagonist in terms of clinical,
laboratory and imaging parameters have generally demon-
strated good responses, even though two randomized
double-blind studies did not show better efficacy than IA
glucocorticoids [9, 14]. Therefore, IA administration of a
TNF antagonist could be an effective treatment in some
patients with refractory monoarthritis, but a method for
selecting patients potentially responsive to this innovative
treatment is not yet available.
We have previously reported prolonged remission of per-
sistent knee monoarthritis in a patient with undifferentiated
SpA after a single 100-mg dose of IA infliximab, monitoring
response to treatment using scintigraphy with 99mTc-inflixi-
mab. Imaging before treatment showed intense uptake in the
affected knee, indicating high levels of TNF, while the second
scintigraphy performed after 4 months showed no accumula-
tion of the radiopharmaceutical, indicating the absence of
detectable levels of TNF and confirming the efficacy of the
IA infliximab treatment [7].
In the present study, we evaluated the predictive role of
99mTc-infliximab scintigraphy for therapy decision-making
in patients with refractory monoarthritis who were candi-
dates for IA treatment with a TNF antagonist.
Materials and methods
Patients
We studied 12 patients (5 men and 7 women; mean age 40.6
±10.1 years) with active monoarthritis (11 knees and 1
ankle; mean disease duration 8.2±6.9 years) enrolled in
the Rheumatology Unit of Sapienza University of Rome,
Italy. There were 5 patients with RA diagnosed according to
the 1987 ACR criteria [16] and 7 patients with SpA diag-
nosed according to the ESSG criteria [17].
All patients had active monoarthritis that had lasted for at
least 3 months and was refractory to treatment with disease-
modifying antirheumatic drugs (DMARDs) and IA injection
of glucocorticoids. Concomitant treatment with an anti-TNF
drug other than infliximab was not considered an exclusion
criterion; indeed the biological agent was stopped 2 weeks
before and restarted 2 weeks after the IA procedure. The
DMARD dose had to have been stable for at least 6 weeks
before IA injection of infliximab, and IA glucocorticoid
(methylprednisolone 40 mg) had to have been injected in
all patients at least 6 weeks before the procedure.
Regarding DMARD treatment, seven patients (58.3 %)
were taking methotrexate (11.8±3.7 mg weekly, mean±
SD), four patients (33.3 %) were taking sulfasalazine (Sal-
azopyrin, 2±0.7 g daily), and one patient (8.3 %) was taking
hydroxychloroquine (200 mg twice a day). Two patients had
been previously treated with systemic adalimumab (40 mg
every 2 weeks) and one patient with etanercept (50 mg
weekly). The mean treatment period was 17±7.5 months.
None of the patients were receiving concurrent systemic
treatment with infliximab.
A tuberculin skin test and chest radiography were per-
formed just before treatment in patients naive to anti-TNF
therapy. After removing synovial fluid, IA infliximab was
injected at concentration of 10 mg/ml (in sterile water for
injection), according to the manufacturer’s instructions. The
doses of infliximab were 100 mg for the knee and 50 mg for
the ankle. The local Ethics Committee approved the study
and written informed consent was obtained from each en-
rolled patient.
Clinical assessment and ultrasonographic evaluation
Patients were evaluated at baseline, just before IA adminis-
tration of infliximab, and after 12 weeks. The same rheu-
matologist performed a clinical examination evaluating pain
using a visual analogue scale (VAS) that ranged from 0 to
100 according to the pain in the affected joint, and the
degree of swelling and tenderness (no swelling or tender-
ness 0, mild 1, moderate 2, severe 3). As previously de-
scribed, a total arthritis score (range 0–6) was obtained as
the sum of the swelling and tenderness scores [13]. A
complete response was defined as ≥70 % improvement in
both total arthritis score and the VAS score for pain, and a
partial response as ≥50 % improvement in at least either the
total arthritis score or the VAS score for pain [13]. Erythro-
cyte sedimentation rate and C-reactive protein were also
evaluated.
Ultrasonographic examination of the inflamed joint was
performed by the same rheumatologist experienced in mus-
culoskeletal ultrasonography, using a Philips/HP Image
Point HX system with a 10-MHz linear probe. Power Dopp-
ler was used with a pulse repetition frequency of 1,000 Hz, a
gain of 18–30 dB, and a low filter. The joints were examined
according to EULAR guidelines for ultrasonography in
rheumatology [14]. Patients were evaluated at baseline,
and after 12 weeks. An arbitrary scoring system (range 0–
6) for assessment of inflamed joints including synovial
hypertrophy (range 0–3) and power Doppler evaluation
(range 0–3) [11] was applied.
Antibody
Infliximab (Remicade) was provided by Centocor Ortho Bio-
tech (Horsham, PA). Human nonspecific immunoglobulin
(HIG, TechneScan) was provided by Mallinckrodt, Petten,
The Netherlands.
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Scintigraphic evaluation
Infliximab was radiolabelled with 99mTc using a direct meth-
od, as described previously [18]. Anterior and posterior
planar whole-body images were acquired 6 h and 20 h after
intravenous administration of 370–550 MBq (100–150 μg)
of 99mTc-infliximab according to our previous experience
[7]. Planar anterior and posterior images of specific joints
(knee or ankle) were acquired with a Philips Sky-Light dual
head gamma camera fitted with a high-resolution collimator.
Whole-body planar images were acquired on a 1,024×1,024
pixel matrix at a scanning speed of 5 cm/min (at 6 h) or
10 cm/min (at 20 h). Joint-specific images (knee or ankle)
were acquired on a 512×512 pixel matrix for 300 s (at 6 h)
or 600 s (at 20 h).
Scintigraphy with 99mTc-infliximab was performed in
all patients twice. The first scan was performed at the
time of patient recruitment (about 1–2 weeks before IA
therapy) and the second scan was performed 12 weeks
after IA administration of a therapeutic dose of inflix-
imab. For quantitative analysis, OSIRIS software (Uni-
versity Hospital of Geneva, Switzerland) was used to
draw regions of interest (ROI) for evaluation of the
target-to-background (T/B) ratio. For the target, a circu-
lar ROI was drawn on the affected joint, and for the
background a rectangular ROI was drawn approximately
5 cm below the knee or above the ankle. Both pre- and
posttherapy images were evaluated together using the
same ROIs. The activity in the ROIs was normalized
to the area of the ROI and divided by the background
activity to obtain the T/B ratio for each joint. The T/B
ratio was calculated for affected and nonaffected joints,
in images acquired at 6 h (T/B6h) and at 20 h (T/B20h).
The T/B ratio increase over time (T/B20h-6h) was also
calculated as an index of specific 99mTc-infliximab bind-
ing to TNF in the joints and expressed in absolute
values and as the percentage increase at 20 h with
respect to 6 h (%T/B20h/6h).
In addition, two patients were also studied with
99mTc-HIG, and therefore four 99mTc-HIG scans were
performed. Before therapy a 99mTc-HIG was performed
and a 99mTc-infliximab scan was performed within a
week (typically the 99mTc-HIG scan was on Monday
or Tuesday and the 99mTc-infliximab scan was on
Wednesday or Thursday or on Thursday or Friday).
The scans were performed again within a week 12 weeks
after IA infliximab therapy. HIG was radiolabelled with
99mTc according to the manufacturer’s instructions.
Whole-body and joint-specific scintigraphic images were
acquired using the same settings as for 99mTc-infliximab
at 6 h and 20 h after intravenous administration of 370–
550 MBq (500 μg) of 99mTc-HIG.
Statistical analysis
Wilcoxon’s paired test was used to compare quantitative
variables in the same group. Spearman’s test was used for
correlation analysis. Student’s t-test was used for analysis of
the T/B ratios from the scintigraphic images since the data
were normally distributed.
Results
Clinical assessment and ultrasonographic evaluation
Table 1 shows the clinical, laboratory and ultrasonographic
parameters before and 12 weeks after IA administration of
infliximab. Significant reductions in the mean VAS scores
for pain, the mean total arthritis scores and the ultrasonog-
raphy scores were recorded. Of the 12 patients, 9 (75 %)
showed a response to IA therapy (6 had a complete re-
sponse, and 3 had a partial response) and 3 did not respond
to therapy (nonresponders).
Table 1 Clinical, laboratory and ultrasonographic parameters before and 12 weeks after IA administration of infliximab. Values are means±SD
Parameter All patients (n012) RA patients (n05) SpA patients (n07)
Baseline 12 weeks p
value
Baseline 12 weeks p
value
Baseline 12 weeks p
value
VAS score for pain 62.4±25.7 19.1±16.2 0.0004 56±27.7 17.2±7.3 NS 67±25.3 16.8±15.4 0.03
Total arthritis score 5±1 1.7±2.6 0.0005 5±1 1.4±1.5 0.05 5±1.1 1.3±1.1 0.01
Erythrocyte sedimentation rate
(mm/h)
17.3±8.5 17.4±5.1 NS 20.4±7.3 18.4±6.2 NS 15.1±9.1 13±6.5 NS
C-reactive protein (mg/dl) 8.1±6 6.4±2.8 NS 10.2±8.4 7.2±3.4 NS 6±2.9 11±11.2 NS
Ultrasonography score 5.4±1.4 1±1.3 0.00002 5.2±1.8 0.4±0.5 0.05 5.5±1.1 0.8±0.8 0.01
NS not significant
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Scintigraphic evaluation
The labelling efficiency of 99mTc-infliximab was always
>95 % with a negligible amount of colloids (<2 %). Quan-
titative analysis of the acquired images (T/B ratio) showed a
higher uptake in the affected than in the nonaffected contra-
lateral joints (1.78±0.46 vs. 1.29±0.27 at 6 h, p00.006;
2.05±0.5 vs. 1.41±0.36 at 20 h, p00.002; Fig. 1a, b). The
mean uptake in the affected joints at 20 h was also signifi-
cantly higher than at 6 h (p00.0004). Most importantly,
responders showed a significantly greater increase in uptake
from 6 h to 20 h than nonresponders in the affected joints
(%T/B20h/6h 20.37±2.9 % vs. 1.98±1.3 %, p00.00001; T/
B20h-6h 0.43±1.3 vs. 0.04±0.02, p00.0007). Partial res-
ponders showed a smaller increase than responders (%T/
B20h/6h 11.73±3.9 %, vs. 20.37±2.9 % p00.003; T/B20h-6h
0.22±0.02 vs. 0.43±0.13, p00.01) and a greater increase
than nonresponders (%T/B20h/6h 11.73±3.9 vs. 1.98±1.3 %,
p00.008; T/B20h-6h 0.22±0.02 vs. 0.04±0.02, p00.0001),
indicating that the more TNF is present in the lesion (and
therefore detected by anti-TNF antibodies) the more is the
therapeutic benefit of IA therapy with infliximab (Fig. 1c).
Fig. 1 a, b T/B6h ratios
determined by 99mTc-infliximab
scintigraphy before and after
IA infliximab therapy in (a)
affected joints and (b)
nonaffected joints. c, d
T/B20h ratios determined by
99mTc-infliximab scintigraphy
before and after IA infliximab
therapy in (c) affected joints
and (d) nonaffected joints.
e %T/B20h/6h before and after
therapy in affected joints.
All responders (squares)
showed a significant decrease
in %T/B20h/6h after therapy
(p00.000003), while
nonresponders (circles) did not
show a decrease. Indeed, all
partial responders remained
partial responders, suggesting
they could be retreated with the
same therapy. Of the
nonresponders, one patient
remained a nonresponder, one
became a partial responder and
one became a responder,
suggesting that all patients
could potentially become
responders with time.
f T/B20h-6h before and after
therapy in affected joints.
Responders showed a
significantly greater decrease in
T/B20h-6h after therapy in
relation to before therapy in
affected joints (p00.00005),
but partial responders showed a
smaller decrease in T/B20h-6h
after therapy (p00.125), while
nonresponders did not show
any decrease in T/B20h-6h after
therapy (p00.109)
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Scintigraphy showed a significant decrease in the T/B ratio
of the affected joints 6 h (from 1.78±0.46 to 1.4±0.3; p0
0.0001) and 20 h after therapy (from 2.05±0.5 to 1.5±0.4; p0
0.0001), indicating a reduction in TNF in the joint after IA
therapy, whereas nonaffected contralateral joints did not show
marked differences in the T/B ratio at either 6 h (from 1.29±
0.27 to 1.2±0.2; p00.0074) or 20 h after therapy (from 1.41±
0.36 to 1.3±0.3; p00.08; Table 2).
Responders also showed a significant decrease in T/B20h-6h
uptake after therapy in comparison with before therapy in the
affected joint (0.43±1.3 vs. 0.08±0.06, p00.00005), but par-
tial responders showed a smaller decrease in T/B20h-6h uptake
after therapy (0.22±0.02, vs. 0.20±0.02, p00.125), and non-
responders did not show any decrease in T/B20h-6h uptake after
therapy (0.04±0.02 vs. 0.23±0.23, p00.109; Fig. 1f).
T/B20h-6h was also significantly correlated with the ar-
thritis score (R200.821, p00.0004), swelling score (R20
0.758, p00.0002), tenderness score (R200.758, p00.001),
ultrasonography score (R200.417, p00.00002) and VAS
score for pain (R200.034, p00.0003; Fig. 2).
Figure 3 shows scintigraphic images in a representative
patient with decreased uptake of 99mTc-infliximab in the
affected joint at 12 weeks after therapy.
99mTc-HIG scan also showed higher joint uptake before
therapy in affected knees (T/B ratios 2.14 and 1.61 at 6 h,
and 2.22 and 1.7 at 20 h) than in nonaffected knees, but
there was no significant increase in the uptake from 6 h to
20 h (T/B20h-6h 0.08 and 0.09), in contrast to the observa-
tions with 99mTc-infliximab (T/B20h-6h 0.43 and 0.58).
99mTc-HIG uptake in knees did not show any apparent
relationship with clinical parameters in the two patients.
The 99mTc-HIG scans after therapy failed to show signifi-
cant decreases in uptake in either patient, in contrast to the
observations with 99mTc-infliximab (Table 3).
No adverse events or infusion-related reactions were
observed in patients undergoing 99mTc-infliximab or
99mTc-HIG scans.
Discussion
The results of the present investigation suggest that 99mTc-
infliximab scintigraphy could be a useful tool for predicting
the clinical response to IA infliximab treatment in patients
with refractory monoarthritis. IA therapy is a frequently
used procedure in the treatment of persistent inflammatory
monooligoarthritis. When properly indicated and per-
formed, it carries minimal risk for the patient. Several dif-
ferent compounds can be injected, among which
glucocorticoids are the most commonly used.
In recent years some experience with IA administration
of TNF-antagonists in patients with refractory monoarthritis
has been reported with contrasting results. The first pub-
lished studies, which included patients treated with IA
infliximab, had important limitations including small sam-
ple sizes and short follow-up durations [4–7]. In 2008, we
described the efficacy and safety of IA infliximab adminis-
tration in a larger cohort of patients (17 patients. 10 with RA
and 7 with PsA) evaluated clinically and ultrasonographi-
cally. In that study, a clinical response was seen 12 weeks
after treatment in 90 % of RA patients and in 57.1 % of PsA
patients. The ultrasonographic evaluation of synovial hyper-
trophy and the power Doppler signal showed significant
decreases in joint inflammation [11]. This was the reason
we selected the 12-week time-point for evaluating response
to the IA infliximab therapy.
Different results were obtained in a more recent random-
ized clinical trial, which included a total of 41 IA injections
(20 infliximab and 21 methylprednisolone) in 28 knees in 23
patients with recurrent knee monoarthritis despite previous
Fig. 1 (continued)
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IA glucocorticoid therapy [14]. Patients were clinically
evaluated using an arbitrary knee joint score, ranging from
0 to 7, encompassing knee tenderness and swelling and a
VAS score for knee pain. In that study, all patients treated
with IA infliximab were retreated within 6 months because
of an insufficient response, while 54 % of initial IA gluco-
corticoid injections were effective without relapse during
6 months of follow-up [14].
These heterogeneous results indicate the need for prog-
nostic factors able to identify patients who are potential
candidates for IA treatment with TNF-antagonist drugs. In
the present study we analysed the role of scintigraphy with
99mTc-infliximab in predicting the response to IA infliximab
in patients with refractory monoarthritis, helping to select
potential responders. The use of imaging with radiolabelled
monoclonal antibodies and cytokine antagonists, such as the
anti-TNF monoclonal antibody infliximab, is a new strategy
that might provide the possibility to perform ‘evidence-
based biological therapy’ of arthritis with a view to assess-
ing whether an antibody will localize in an inflamed joint
before using the same unlabelled antibody therapeutically
[19, 20]. In a previous case study, the response to IA
infliximab in a patient with SpA and persistent knee mono-
arthritis was monitored using 99mTc-infliximab scintigraphy.
Clinical and laboratory improvement was associated with
scintigraphy findings that showed the absence of 99mTc-
infliximab accumulation in the affected knee 4 months after
IA infliximab administration [7].
In the present study, we confirmed the clinical efficacy of
IA infliximab treatment: after 12 weeks 75 % of treated
patients showed a clinical response that was a complete
response in 66.7 % of responders. The ultrasonographic
features of synovitis significantly improved during follow-
up and were correlated positively with the outcome meas-
ures. Moreover, the efficacy of IA infliximab was evaluated
by 99mTc-infliximab scintigraphy, which showed 12 weeks
after treatment a significant decrease in the T/B ratio of the
affected joint at 6 h and 20 h. This response suggests a
reduction in TNF in the affected joint and an improvement
in the inflammatory status. However, the most interesting
aspect was the baseline scan that predicted a response to
treatment after 12 weeks.
In the pretherapy scan, responders showed significant-
ly greater increases during the period 6 h to 20 h in than
nonresponders. A possible explanation for the 99mTc-
infliximab uptake in the early scan (6 h after injection)
is the increased vascularity and joint swelling, particular-
ly in those patients in whom the main complaint was
oedema and/or pain. Retention of mAb in joints and its
further accumulation at 20 h can be interpreted as the
consequence of the specific binding of 99mTc-TNF mAb
to the TNF expressed by different cell populations in-
cluding macrophages, monocytes, neutrophils, T cells and
NK cells, and/or to soluble TNF in inflamed joints.
Partial responders showed a smaller increase in T/B ratio
between 6 h and 20 h. We can hypothesise that in
patients with lower expression of TNF in affected joints,
99mTc-TNF mAb can enter the joint at early time points
due to inflammation, followed by little retention and
washout due to the absence of specific binding sites. A
similar phenomenon (i.e. the increase of joint uptake with
time of a radiolabelled mAb in patients with severe
Table 2 Average scintigraphic scores for 99mTc-infliximab in all patients (n012)
Joint Before treatment After treatment
T/B6h T/B20h T/B20h-6h (%T/B20h/6h) T/B6h T/B20h T/B20h-6h (%T/B20h/6h)
Affected joint 1.78±0.46a 2.05±0.5b 0.28±0.19c (13.61±8.34)n 1.4±0.3d 1.5±0.4e 0.15±0.13f (8.81±5.8)q
Nonaffected contralateral joint 1.29±0.27g 1.41±0.36h 0.12±0.11i (7.86±5.43)r 1.2±0.2j 1.3±0.3l 0.11±0.10m (8.2±7.94)s
p values:
a: vs. b 0.0004, vs. d 0.0001, vs. g 0.006
b: vs. e 0.0001, vs. h 0.002
c: vs. f 0.120, vs. i 0.025
d: vs. e 0.002, vs. j 0.096
e: vs. l 0.108
f: vs. m 0.464
g: vs. h 0.0028, vs. j 0.0074
h: vs. l 0.08
i: vs. m 0.8
n: vs. q 0.11, vs. r 0.01
q: vs. s 0.8
r: vs. s 0.8
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inflammation) has also previously been described in
patients with RA using 99mTc-labelled anti-CD3 mAb
[21]. In our study responders showed much higher T/
B20h-6h in affected joints than nonresponders, whereas
partial responders showed an intermediate T/B20h-6h. T/
B20h-6h in affected joints also correlated with several
Fig. 2 a–e Correlations between increases in T/B ratio in affected
joints from 6 h to 20 h and clinical parameters (a arthritis score, b
swelling score, c tenderness score, d ultrasonographic score, e VAS
score). f T/B20h-6h values before therapy in all patients (squares com-
plete responders, triangles partial responders, circles nonresponders)
Fig. 3 Scintigraphic imaging
with 99mTc-infliximab at 20 h
(a) before and (b) 12 weeks
after IA infliximab therapy.
Higher uptake is seen in the left
knee before therapy (a) and
much lower uptake is seen in
the left knee after therapy (b).
Clinical evaluation confirmed
that this patient responded to
therapy. The ROIs for the target
(circles) and background
(rectangles) from which the T/
B ratios were calculated are also
shown
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clinical parameters, indicating that this semiquantitative
scintigraphic index can predict success of IA therapy.
IA infliximab was also efficacious in the three patients
who had been receiving systemic TNF antagonists other
than infliximab without any significant clinical benefit. We
can speculate that changing the anti-TNF antibody for ther-
apy and changing the route of administration may result in a
good clinical response. Alternatively, patients who were not
responders may become responders over time. Interestingly,
no significant change in T/B ratio in nonaffected contralat-
eral joints was observed, indicating that after IA therapy not
enough infliximab escapes from the treated joint to affect
the course of disease in other joints.
99mTc-HIG that has been proposed for imaging of inflam-
mation in RA [22, 23] did not show any increase in T/B
ratio at 20 h in the pretherapy scintigraphy with respect to
the ratio at 6 h in either of the patients studied, and behaved
differently from infliximab. This difference in behaviour of
the two radiopharmaceuticals reflects the different uptake
mechanisms involved in their accumulation process. Indeed,
contrary to radiolabelled infliximab, the accumulation of
radiolabelled HIG at the site of inflammation is mainly
nonspecific and is related to the increase in vascularization,
extracellular fluid volume, endothelial permeability and sy-
novial fluid clearance in inflamed joints [24, 25]. Moreover,
99mTc-HIG was not able to demonstrate changes in disease
activity after IA treatment with infliximab in the two patients,
as confirmed by clinical evaluation, and consequently this
radiopharmaceutical did not help therapy decision-making in
these two patients.
Here we showed that scintigraphy with 99mTc-anti-TNF
mAb can play a role in therapy decision-making, and in the
selection of patients with RA as candidates for IA infliximab
therapy. Lower TNF expression may suggest the use of a
different therapy, directed towards other inflammatory tar-
gets. Therefore, in future, 99mTc-anti-TNF mAb scintigra-
phy could play a role in selecting the best therapeutic option
for the individual patient, avoiding the extra cost burden of
unnecessary anti-TNF therapies. However, a large prospec-
tive study is required to determine the predictive value of
this technique. If we succeed in doing this, we will not only
improve the clinical care of these patients but also provide a
means to apply biological therapies in a cost-effective
manner.
Conflicts of interest None.
References
1. Scott DL, Kingsley GH. Tumour necrosis factor inhibitors for
rheumatoid arthritis. N Engl J Med. 2006;355:704–12.
2. Deleuran BW, Chu CQ, Field M, Brennan FM,Mitchell T, Feldmann
M, et al. Localization of tumor necrosis factor receptors in the
synovial tissue and cartilage-pannus junction in patients with rheu-
matoid arthritis. Implications for local actions of tumor necrosis
factor alpha. Arthritis Rheum. 1992;35:1170–8.
3. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J
Med. 2004;350:2167–79.
4. Bokarewa M, Tarkowski A. Local infusion of infliximab for the
treatment of acute joint inflammation. Ann Rheum Dis.
2003;62:783–4.
5. Nikas SN, Temekonidis TI, Zikou AK, Argyropoulou MI, Efremidis
S, Drosos AA. Treatment of resistant rheumatoid arthritis by intraar-
ticular infliximab injections: a pilot study. Ann Rheum Dis.
2004;63:102–3.
6. Schatteman L, Gyselbrecht L, De Clercq L,Mielants H. Treatment of
refractory inflammatory monoarthritis in ankylosing spondylitis by
intraarticular injection of infliximab. J Rheumatol. 2006;33:82–5.
7. Conti F, Priori R, Chimenti MS, Coari G, Annovazzi A, Valesini G,
et al. Successful treatment with intraarticular infliximab for resis-
tant knee monoarthritis in a patient with spondyloarthropathy. A
role for scintigraphy with 99mTc-infliximab. Arthritis Rheum.
2005;52:1224–46.
8. Alstergren P, Larsson PT, Kopp S. Successful treatment with
multiple intra-articular injections of infliximab in a patient with
psoriatic arthritis. Scand J Rheumatol. 2008;37(2):155–7.
9. Bliddal H, Terslev L, Qvistgaard E, Recke P, HolmCC, Danneskiold-
Samsoe B, et al. Safety of intra-articular injection of etanercept in
small-joint arthritis: an uncontrolled, pilot-study with independent
imaging assessment. Joint Bone Spine. 2006;73(6):714–7.
10. Boesen M, Boesen L, Jensen KE, Cimmino MA, Torp-Pedersen S,
Terslev L, et al. Clinical outcome and imaging changes after
intraarticular (IA) application of etanercept or methylprednisolone
in rheumatoid arthritis: magnetic resonance imaging and
ultrasound-Doppler show no effect of IA injections in the wrist
after 4 weeks. J Rheumatol. 2008;35(4):584–91.
11. Conti F, Ceccarelli F, Priori R, Iagnocco A, Signore A, Valesini G.
Intra-articular infliximab in patients with rheumatoid arthritis and
psoriatic arthritis with monoarthritis resistant to local glucocorticoids.
Table 3 Scintigraphic scores for 99mTc-infliximab and 99mTc-HIG scans in patients 4 and 12 who underwent both scans
Radiopharmaceutical Before treatment After treatment

























99mTc-infliximab 1.8 2.23 0.43 1.32 1.90 0.58 1.4 1.5 0.1 1.14 1.31 0.17
99mTc-HIG 2.14 2.22 0.08 1.61 1.70 0.09 2.1 2.17 0.07 1.56 1.60 0.04
1346 Eur J Nucl Med Mol Imaging (2012) 39:1339–1347
Clinical efficacy extended to patients on systemic anti-tumour necro-
sis factor alpha. Ann Rheum Dis. 2008;67(12):1787–90.
12. Haroon M, O'Gradaigh D. Efficacy and safety of combining intra-
articular methylprednisolone and anti-TNF agent to achieve pro-
longed remission in patients with recurrent inflammatory monoar-
thritis. Joint Bone Spine. 2010;77(3):232–4.
13. Fioravanti A, Fabbroni M, Cerase A, Galeazzi M. Treatment of
erosive osteoarthritis of the hands by intra-articular infliximab
injections: a pilot study. Rheumatol Int. 2009;29(8):961–5.
14. Backhaus M, Burmester GR, Gerber T, Grassi W, Machold KP,
Swen WA, et al. Guidelines for musculoskeletal ultrasound in
rheumatology. Ann Rheum Dis 2001;60(7):641–9.
15. Fiocco U, Sfriso P, Oliviero F, Roux-Lombard P, Scagliori E,
Cozzi L, et al. Synovial effusion and synovial fluid biomarkers
in psoriatic arthritis to assess intraarticular tumor necrosis factor-α
blockade in the knee joint. Arthritis Res Ther. 2010;12(4):R148.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF,
Cooper NS, et al. The American Rheumatism Association 1987
revised criteria for the classification of rheumatoid arthritis. Ar-
thritis Rheum. 1988;31:315–24.
17. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B,
Calin A, et al. The European Spondylarthropathy Study Group
preliminary criteria for the classification of spondylarthropathy.
Arthritis Rheum. 1991;34:1218–27.
18. D’Alessandria C, Malviya G, Viscido A, Aratari A, Maccioni F,
Amato A, et al. Use of a 99mTc labeled anti-TNFalpha monoclonal
antibody in Crohn's disease: in vitro and in vivo studies. Q J Nucl
Med Mol Imaging. 2007;51:1–9.
19. Chapman PT, Jamar F, Keelan ET, Peters AM, Haskard DO. Use of
a radiolabeled monoclonal antibody against E-selectin for imaging
of endothelial activation in rheumatoid arthritis. Arthritis Rheum.
1996;39:1371–5.
20. Jamar F, Chapman PT, Manicourt DH, Glass DM, Haskard DO,
Peters AM. A comparison between 111In-anti-E-selectin mAb and
99mTc-labelled human non-specific immunoglobulin in radionuclide
imaging of rheumatoid arthritis. Br J Radiol. 1997;70:473–81.
21. Lopes FP, de Azevedo MN, Marchiori E, da Fonseca LM, de
Souza SA, Gutfilen B. Use of 99mTc-anti-CD3 scintigraphy in
the differential diagnosis of rheumatic diseases. Rheumatology.
2010;49:933–9.
22. van der Lubbe PA, Arndt JW, Calame W, Ferreira TC, Pauwels
EK, Breedveld FC. Measurement of synovial inflammation in
rheumatoid arthritis with technetium-99m labelled human poly-
clonal immunoglobulin G. Eur J Nucl Med. 1991;18:119–23.
23. de Bois MH, Arndt JW, van der Velde EA, van der Lubbe PA,
Westedt ML, Pauwels EK, et al. 99mTc human immunoglobulin
scintigraphy – a reliable method to detect joint activity in rheuma-
toid arthritis. J Rheumatol. 1992;19:1371–6.
24. Signore A, Mather SJ, Piaggio G, Malviya G, Dierckx RA. Mo-
lecular imaging of inflammation/infection: nuclear medicine and
optical imaging agents and methods. Chem Rev. 2010;110
(5):3112–45.
25. Malviya G, Galli F, Sonni I, Pacilio M, Signore A. Targeting T and
B lymphocytes with radiolabelled antibodies for diagnostic and
therapeutic applications. Q J Nucl Med Mol Imaging. 2010;54
(6):654–76.
Eur J Nucl Med Mol Imaging (2012) 39:1339–1347 1347
